Microsized Curcumin Lozenges for Oral Transmucosal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemopreventive agents for head and neck squamous cell cancer (HNSCC) face challenges due to poor bioavailability and toxicity issues, with curcumin having limited efficacy due to low gastrointestinal absorption and requiring high doses, making it difficult for patients to swallow large pills, especially post-surgery or during radiation therapy.
Innovation Solution
The development of microsized curcumin particles for oral transmucosal delivery, formulated as lozenges or gums, which increase water solubility and allow gradual release of curcumin into the mucosal membrane, enhancing systemic absorption and bioavailability, with a pH buffer maintaining the environment at 4.5-6.5 to facilitate absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of curcumin are administered to overcome poor bioavailability, then therapeutic efficacy is improved, but patient compliance deteriorates due to difficulty swallowing large pills
Solution Approach 1:
The curcumin is divided into microsized particles (1-500 micrometers) which can be incorporated into multiple smaller dosage forms such as lozenges or capsules, allowing the total therapeutic dose to be administered in divided portions that are easier to swallow while maintaining bioavailability
Solution Approach 2:
The invention transitions from oral gastrointestinal absorption to oral transmucosal absorption through the buccal mucosa, representing a dimensional change in the absorption pathway that enables better bioavailability at lower doses and improved patient comfort
2Ease of operation
If curcumin is formulated for oral gastrointestinal absorption, then administration is simple, but bioavailability remains poor due to low absorption
Solution Approach 1:
The invention shifts the absorption route from the gastrointestinal tract to the oral mucosa, utilizing the highly vascularized buccal membrane as an alternative absorption pathway that bypasses gastrointestinal limitations and achieves superior bioavailability
Solution Approach 2:
The curcumin particles are engineered with specific size parameters (1-500 micrometers) and the formulation maintains specific pH conditions (4.5-6.5) to optimize mucosal penetration and absorption kinetics, transforming the physical-chemical parameters to enhance bioavailability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases serum curcumin levels, achieving therapeutic concentrations that down-regulate cancer-related biomarkers, such as FGF-2, GRO, MIP-1b, IP-10, and TNFα, providing effective chemoprevention with reduced toxicity and improved patient compliance by avoiding swallowing difficulties.
Implementation Method 1
a buffer to maintain the pH at 4.5-6.5
Implementation Method 2
increase water solubility and allow gradual release of curcumin into the mucosal membrane
Implementation Method 3
allow gradual release of curcumin into the mucosal membrane
Data Source
Figure 1~2B
Figure 3A~3B
Figure 4
AI summary
Disclosed herein are formulations for the local delivery of therapeutically effective doses of curcumin that provide sufficient serum levels of curcumin to treat diseases such as head and neck disorders and upper aerodigestive disorders.